Press release

American Diabetes Association Announces New Editors of Diabetes Care

August 5, 2022 | Arlington, Virginia

The American Diabetes Association® (ADA) announced today the appointment of Steven E. Kahn, MB, ChB, as the incoming editor in chief of Diabetes Care®, the highest-ranked journal devoted to original diabetes-related research. Dr. Kahn is professor of medicine in the Division of Metabolism, Endocrinology and Nutrition at the University of Washington and a staff physician with the VA Puget Sound Health Care System.

The ADA also announces the appointments of Cheryl A.M. Anderson, PhD, MPH, MS, of the University of California, San Diego; John B. Buse, MD, PhD, of the University of North Carolina at Chapel Hill; and Elizabeth Selvin, PhD, MPH, of Johns Hopkins University, as deputy editors of Diabetes Care

In addition, the following individuals have been appointed associate editors on the editorial team of Diabetes Care:

  • Sonia Y. Angell, MD, MPH, DTM&H, FACP, Johns Hopkins University
  • Vanita R. Aroda, MD, Brigham and Women’s Hospital
  • Jessica R. Castle, MD, Oregon Health & Science University
  • Thomas P.A. Danne, MD, Hannover Medical School, Hannover, Germany
  • Justin B. Echouffo Tcheugui, MD, PhD, MPhil, Johns Hopkins University
  • Alison E. Field, ScD, Brown University
  • Jose C. Florez, MD, PhD, Harvard University
  • Meghana D. Gadgil, MD, MPH, University of California, San Francisco
  • Amalia Gastaldelli, PhD, Istituto di Fisiologia Clinica CNR, Pisa, Italy
  • Jennifer B. Green, MD, Duke University
  • Ania M. Jastreboff, MD, PhD, Yale University
  • Alka M. Kanaya, MD, University of California, San Francisco
  • Namratha R. Kandula, MD, MPH, Northwestern University
  • Csaba P. Kovesdy, MD, FASN, University of Tennessee
  • Kristen J. Nadeau, MD, MS, University of Colorado
  • Rodica Pop-Busui, MD, PhD, University of Michigan
  • Camille E. Powe, MD, Harvard University
  • Casey M. Rebholz, PhD, MS, MNSP, MPH, FAHA, Johns Hopkins University
  • Naveed Sattar, FMedSci, FRCPath, FRCPGlas, FRSE, University of Glasgow, Glasgow, Scotland
  • Jonathan E. Shaw, MD, MRCP (U.K.), FRACP, Baker Heart and Diabetes Institute, Melbourne, Australia
  • Emily K. Sims, MD, Indiana University
  • Kristina M. Utzschneider, MD, VA Puget Sound Health Care System and University of Washington
  • Adrian Vella, MD, FRCP(Edin), Mayo Clinic
  • Cuilin Zhang, MD, MPH, PhD, National University of Singapore and Johns Hopkins University

The incoming editors will serve a three-year term for the 2023–2025 volume years with an optional two-year extension.

In addition to his role as professor of medicine and adjunct professor of laboratory medicine and pathology at the University of Washington, Dr. Kahn is a staff physician at VA Puget Sound Health Care System, where he practices endocrinology and undertakes much of his research. He leads several initiatives at the University of Washington, including directing the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-funded Diabetes Research Center and NIDDK-funded Diabetes, Obesity and Metabolism Training Program.

Dr. Kahn’s research focuses on the role of the islet β-cell in the pathogenesis and treatment of prediabetes and type 2 diabetes. He performs physiological studies in humans and has an extensive basic research program examining the loss of β-cells in type 2 diabetes. He has participated and held leadership positions in several major clinical trials related to type 2 diabetes, including the Diabetes Prevention Program (DPP) and its follow-up, the Diabetes Prevention Program Outcomes Study (DPPOS); Look AHEAD (Action for Health in Diabetes); Restoring Insulin Secretion (RISE) Study; and Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).

Dr. Kahn has received numerous awards for his research, including the Endocrine Society’s Clinical Investigator Award, the Department of Veterans Affairs’ John B. Barnwell Award, the European Association for the Study of Diabetes’ Albert Renold and Claude Bernard awards, and the American Diabetes Association’s Outstanding Achievement in Clinical Diabetes Research Award.

“We are thrilled and honored to welcome Dr. Kahn as the new editor in chief of Diabetes Care,” said Dr. Robert Gabbay, chief scientific and medical officer of the ADA. “The ground-breaking research published in Diabetes Care is fundamental to the ADA mission, and we look forward to working with Dr. Kahn and his new editorial team on ways to expand the reach and influence of the high-impact content published in the journal.”

“I am excited to be following in the footsteps of numerous great editors who have made Diabetes Care the preeminent journal in clinical diabetes,” stated Dr. Kahn. “The new editorial team is more representative of the Diabetes Care readership as well as populations affected by diabetes. We plan to increase submissions addressing issues related to the equity of health care delivery and outcomes for people with diabetes, thereby moving Diabetes Care towards being a premier journal promoting attention to health equity.” 

Dr. Kahn and his editorial team will succeed Editor in Chief Matthew C. Riddle, MD, and his editorial team, which convened in April 2017. Their term will complete at the end of 2022. Dr. Riddle’s team includes the following associate editors:

  • George Bakris, MD
  • Lawrence Blonde, MD, FACP
  • Andrew J.M. Boulton, MD
  • David A. D’Alessio, MD
  • Mary de Groot, PhD
  • Linda A. DiMeglio, MA, MD, MPH
  • Linda Gonder-Frederick, PhD
  • Korey K. Hood, PhD
  • Frank B. Hu, MD, MPH, PhD
  • Sanjay Kaul, MD, FACC, FAHA
  • Lawrence A. Leiter, MD
  • Robert G. Moses, MD
  • Stephen S. Rich, PhD
  • Julio Rosenstock, MD
  • William V. Tamborlane, MD
  • Judith Wylie-Rosett, EdD, RD

Drs. Kahn, Aroda, Castle, Selvin, and Vella also served on Dr. Riddle’s team.

# # #


About the American Diabetes Association
The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 81 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 133 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).